IMPEDIMED LIMITED — Board/Management Information 2020

Mar 19, 2020

20 March 2020

==> picture [129 x 31] intentionally omitted <==

ASX ANNOUNCEMENT

Executive Management Changes

Brisbane, Australia – ImpediMed Limited (ASX: IPD) today advises Mr. Morten Vigeland, Chief Financial Officer (CFO), has decided to leave the company for personal reasons. Morten has been an important member of ImpediMed’s senior management team for the past seven years and has led the finance function and many successful initiatives that have contributed to the company’s development.

Morten has been transitioning his CFO duties to Timothy Cruickshank over a period of time to ensure continuity. With Morten’s departure, Tim has now been promoted to Executive Vice President of Finance, reporting directly to Richard Carreon, Managing Director and CEO, and will serve as interim CFO. Tim has been a member of the finance team for over twelve years, most recently as VP of Finance for the last four years. “We are very appreciative of Tim taking on additional responsibilities as duties were gradually transitioned. He has a proven track record of strong financial management, SaaS modeling and strategy. In addition, his intricate knowledge of our financial procedures and controls will provide seamless continuity to the finance team,” commented Mr. Carreon.

Mr Carreon said: “Morten has been our CFO since 2013 and has been a valued member of the management team. We are grateful for his guidance and strategic leadership during a transformative stage of the Company moving from clinical to commercialisation and for his huge contribution to the success of the business. I would like to thank him for his work over many years and wish him every success in the future. The company is firmly on track to deliver its plans for the future, continuing our leadership of the world’s most advanced non-invasive bioimpedance spectroscopy (BIS) device for assessing fluid status and tissue composition.”

Authorised for release by the Board.

Contact Details

Investor Relations Contact: Media Contact: Mike Bassett, ImpediMed Kyahn Williamson, WE Buchan T : +61 407 431 432 T: +61 3 9866 4722 E: mbassett@impedimed.com E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.